Gastroenterology
EMD Serono, Inc. provides the first new drug treatment option for patients with short bowel syndrome (SBS) in more than 35 years. Zorbtive™ [somatropin (rDNA origin) for injection] is approved to treat patients with SBS requiring specialized nutritional support. Zorbtive™ is the only human growth hormone approved by the FDA for the treatment of short bowel syndrome, and has orphan drug market exclusivity through 2010.
Short Bowel Syndrome
Short bowel syndrome (SBS) is a condition where a significant portion of a person's small intestine or all of the small intestine is removed as a result of chronic underlying condition or trauma. With SBS, the remaining intestine is unable to absorb electrolytes, water or necessary nutrients sufficiently. Until recently, treatment for SBS consisted of parenteral nutrition, which replaces the nutrients lost by the shortened small intestine with a nutrient mix delivered directly to the bloodstream.
Short bowel syndrome (SBS) is a condition where a significant portion of a person's small intestine or all of the small intestine is removed as a result of chronic underlying condition or trauma. With SBS, the remaining intestine is unable to absorb electrolytes, water or necessary nutrients sufficiently. Until recently, treatment for SBS consisted of parenteral nutrition, which replaces the nutrients lost by the shortened small intestine with a nutrient mix delivered directly to the bloodstream.
| Disclaimer |
| This site contains medical information that is intended for residents of the United States only and is not meant to be a substitute for the advice provided by a medical professional. Always consult a healthcare provider if you have health concerns. For residents outside of the US, please go to www.merckserono.com for information. |
